李氏大藥廠(00950.HK)前三季度純利1.22億港元 同比增長51.9%
格隆匯11月26日丨李氏大藥廠(00950.HK)公佈,截至2020年9月30日止9個月,公司收入8.94億港元,同比減少2.2%;毛利5.76億港元,同比減少4.2%;公司擁有人應占溢利1.22億港元,同比增長51.9%;每股盈利20.75港仙。
在對抗COVID-19疫情的同時,集團的新藥研究及開發活動自本年度第二季以來已逐步恢復。於2020年前9個月,研發活動的開支為2.69億港元(上年同期:2.29億港元),相當於回顧期內收益的30.0%(上年同期:25.1%)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.